Shibata Hirofumi, Saito Shin, Uppaluri Ravindra
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Department of Otolaryngology, Gifu University Graduate School of Medicine, Gifu, Japan.
Front Oncol. 2021 Sep 6;11:727433. doi: 10.3389/fonc.2021.727433. eCollection 2021.
Neoadjuvant immunotherapy has the potential to enhance clinical outcomes by increasing anti-tumor immune responses in the presence of abundant tumor-derived antigen in an immune microenvironment that has not been exposed to previous therapy. The current mainstay of advanced head and neck squamous cell carcinoma (HNSCC) treatment remains surgery and radiotherapy with/without conventional chemotherapy. Despite this multi-modality treatment, advanced human papillomavirus (HPV)-negative HNSCC shows poor prognosis. Treatment intensification with neoadjuvant (induction) chemotherapies with platinum drugs are insufficient to significantly prolong overall survival. Although only 15-20% of patients benefit, immunotherapies have been approved and widely used for recurrent and metastatic HNSCC. These successes have led to checkpoint blockade therapies being testing in earlier treatment settings. Recent clinical trials of neoadjuvant immunotherapy show promising results and this methodology has the potential to change the treatment algorithm of HNSCC. This overview examines the treatment history of neoadjuvant approaches for HNSCC, and especially focuses on the recent topics of neoadjuvant immunotherapy for HNSCC.
新辅助免疫疗法有潜力通过在尚未接触过先前治疗的免疫微环境中，在存在大量肿瘤源性抗原的情况下增强抗肿瘤免疫反应，从而改善临床结果。晚期头颈部鳞状细胞癌（HNSCC）治疗的当前主要手段仍然是手术和放疗，可联合或不联合传统化疗。尽管采用了这种多模式治疗，但晚期人乳头瘤病毒（HPV）阴性的HNSCC预后仍然很差。使用铂类药物进行新辅助（诱导）化疗来强化治疗，不足以显著延长总生存期。尽管只有15%-20%的患者受益，但免疫疗法已被批准并广泛用于复发和转移性HNSCC。这些成功促使检查点阻断疗法正在早期治疗环境中进行试验。新辅助免疫疗法的近期临床试验显示出有希望的结果，这种方法有可能改变HNSCC的治疗方案。本综述探讨了HNSCC新辅助治疗方法的治疗历史，尤其关注HNSCC新辅助免疫疗法的近期话题。
